Trials / Completed
CompletedNCT03612388
Combined Use of a Novel Cardioplegic Formula With Myocardial Protection System (MPS)® Versus Cardioplexol ® in Isolated Coronary Artery Bypass Grafting (CABG) Using MiECC;
Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Isolated CABG Using MiECC (Minimal Extracorporeal Circulation System)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 211 (actual)
- Sponsor
- University Hospital, Basel, Switzerland · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Combined use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation | use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system). |
Timeline
- Start date
- 2010-02-28
- Primary completion
- 2018-03-31
- Completion
- 2019-03-13
- First posted
- 2018-08-02
- Last updated
- 2019-07-31
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03612388. Inclusion in this directory is not an endorsement.